Taltz vs Cosentyx
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Taltz | US Cosentyx | |
|---|---|---|
| Generic name | ixekizumab | secukinumab |
| Drug class | IL-17A Inhibitor (Biologic) | IL-17A Inhibitor (Biologic) |
| Treats | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Eli Lilly | Novartis |
| Year approved | 2016 | 2015 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $190M | $160M |
| Common side effects | Injection site reactions, Respiratory infections, Inflammatory bowel disease, Low white blood cell count | Respiratory infections, Inflammatory bowel disease, Fungal infections, Injection site reactions |
Frequently asked questions
Is Taltz or Cosentyx better?
Neither is universally "better." Taltz (ixekizumab) and Cosentyx (secukinumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Taltz and Cosentyx?
Taltz is a IL-17A Inhibitor (Biologic) made by Eli Lilly, while Cosentyx is a IL-17A Inhibitor (Biologic) made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Taltz has the larger estimated TV advertising budget of the two.